Last updated: July 25, 2026
Executive summary: Bayer Consumer Care AG sued Hetero USA Inc. under the Hatch-Waxman framework in 1:23-cv-01221 in the U.S. District Court for the District of New Jersey. The case caption indicates a patent-infringement/ANDA challenge posture typical of Paragraph IV litigation, with Bayer as the asserted patent-holder and Hetero as the generic applicant. A legally actionable litigation analysis requires the complaint, the asserted patent list, and the case docket events (including any Rule 16 scheduling orders, claim-construction orders, trial dates, settlements, or dismissals). This record is not provided in the prompt, so a complete and accurate patent, infringement, and exclusivity/launch-risk analysis cannot be produced.
What patents are asserted in Bayer Consumer Care AG v. Hetero USA Inc. (1:23-cv-01221)?
No asserted-patent numbers, publication IDs, or claims are provided in the input.
Which patent numbers are listed as the basis for infringement?
Not available.
Who owns the asserted patents in the complaint?
Not available.
What Orange Book listed drug and NDA/ANDA are at issue?
Not available.
What is the procedural posture of 1:23-cv-01221 (complaint, responsive pleadings, claim construction, trial)?
No docket dates or procedural events are provided in the input.
Has the court issued a scheduling order or claim-construction ruling?
Not available.
Were there dispositive motions (12(b)(6), summary judgment) or motions to dismiss?
Not available.
Is the case at pleadings, Markman, discovery, or trial stage?
Not available.
What claims does Bayer allege and what defenses has Hetero raised?
The complaint allegations and Hetero’s defenses are not included in the input.
Are defenses limited to non-infringement and invalidity, or do they include statutory defenses?
Not available.
Is obviousness, anticipation, or lack of written description/enablement raised?
Not available.
How does this litigation affect generic entry risk for Hetero (Paragraph IV timing and 180-day exclusivity)?
No FDA linkage details (ANDA number, Orange Book listing, paragraph IV notice date, exclusivity status) are provided.
When does the 30-month stay expire for the relevant ANDA?
Not available.
Does Hetero have 180-day exclusivity exposure or loss triggers?
Not available.
What is the practical launch window implied by the court’s timeline?
Not available.
What is the FDA regulatory status of the ANDA referenced in 1:23-cv-01221?
No ANDA number, submission type, approval status, or labeling paragraph details are provided.
What is the Orange Book status of the listed patents for the brand drug?
Not available.
What is the mechanism: ANDA vs. 505(b)(2) vs. other?
Not available.
What settlement or injunction outcomes exist for Bayer vs. Hetero in 1:23-cv-01221?
No settlement terms, consent judgments, dismissal orders, or injunction orders are provided.
Was there a standstill agreement, covenant not to sue, or stipulation of dismissal?
Not available.
Were there amended or superseding complaints impacting the asserted patent set?
Not available.
Are there stipulations that narrow the asserted claims or redesign the generic product?
Not available.
How strong is Bayer’s patent estate in this case: validity/infringement likelihood and remaining enforceability?
Strength analysis depends on:
- asserted claims and claim construction,
- identified prior art,
- remaining patent life and terminal disclaimers,
- any co-pending litigations or PTAB challenges.
None of these inputs are provided.
Remaining patent term and expiration dates
Not available.
Related family members or continuation claims
Not available.
Any PTAB challenges or IPR/CBM outcomes referenced in the case
Not available.
How does this case compare with other Bayer vs. Hetero patent litigations (strategy and outcomes)?
No related cases, dockets, or outcome patterns are provided.
Are there prior settlements or recurring disputed technical themes?
Not available.
Is Hetero litigating similar formulations or product strengths?
Not available.
Key Takeaways
Not available because the prompt does not include the case docket or filings needed to extract:
- asserted patents and claims,
- legal theories,
- procedural stage,
- any settlement/injunction outcome,
- and FDA-linked exclusivity/timing effects.
FAQs
-
What court held jurisdiction in Bayer Consumer Care AG v. Hetero USA Inc. (1:23-cv-01221)?
Not available from the provided input.
-
Which patents and claims does Bayer typically assert in Hatch-Waxman cases against Hetero USA?
Not available from the provided input.
-
Does 1:23-cv-01221 indicate a Paragraph IV notice, 30-month stay, or 180-day exclusivity dispute?
Not available from the provided input.
-
What product and strength (dosage form) is likely at issue in this litigation?
Not available from the provided input.
-
Has Hetero USA filed any invalidity or non-infringement arguments that could impact future launches?
Not available from the provided input.
References (APA)
Not available because no source documents or docket materials were provided in the prompt to cite.
